Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: A new emerging superbug?

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 4, 2017, Pages 988-992

  Xisto, Mariana I D S ^a,b   Caramalho, Rita D F ^a   Rocha, Débora A S ^b   Ferreira Pereira, Antonio ^b   Sartori, Bettina ^a   Barreto Bergter, Eliana ^b   Junqueira, Maria L ^c   Lass Flörl, Cornelia ^a   Lackner, Michaela ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE; VORICONAZOLE; CYTOCHROME P450; GLUCOSYLTRANSFERASE; PYRROLE DERIVATIVE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BINDING SITE; BRAZIL; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; ERG11 GENE; FKS1 GENE; FUNGAL GENE; FUNGUS ISOLATION; HOMOZYGOTE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; SEQUENCE HOMOLOGY; UNIVERSITY HOSPITAL; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION;

ANTIFUNGAL AGENTS; AZOLES; BRAZIL; CANDIDA TROPICALIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POINT MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 85018256095     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw558     Document Type: Article

References (35)

1. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from populationbased surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
2. Lackner M, Martin-Vicente A, Lass-Flörl C. Multidrug-and cross-resistant Candida: the looming threat. Curr Fungal Infect Rep 2015; 9: 23-36.
3. Brown GD, Denning DW, Gow NA et al. Hidden killers: human fungal infections. Sci TranslMed 2012; 4: 165rv13.
4. González GM, Treviño-Rangel RJ, Palma-Nicolás JP et al. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. J Antimicrob Chemother 2013; 68: 2847-51.
5. Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.JClinMicrobiol 2005; 43: 5848-59.
6. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstreaminfections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
7. Yang YL, Cheng MF, Wang CWet al. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. MedMycol 2010; 48: 328-34.
8. Wille MP, Guimarães T, Furtado GHC et al. Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil.MemInst Oswaldo Cruz 2013; 108: 288-92.
9. Chen T-C, Chen Y-H, Chen Y-C et al. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents. Kaohsiung J Med Sci 2012; 28: 306-15.
10. Neves-Junior A, Cartagenes-Pinto AC, Rocha DA et al. Prevalence and fluconazole susceptibility profile of Candida spp. clinical isolates in a Brazilian tertiary hospital in Minas Gerais, Brazil. An Acad Bras Ci^enc 2015; 87: 1349-59.
11. Stevenson LG, Drake SK, Shea YR et al. Evaluation ofmatrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. JClinMicrobiol 2010; 48: 3482-6.
12. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth Informational Supplement M27-S4. CLSI, Wayne, PA, USA, 2012.
14. Arendrup MC, Guinea J, Cuenca-Estrella M et al. [Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)]. EUCAST Technical Note on themethod for the determination of broth dilutionminimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14: 982-4.
15. Lackner M, Najafzadeh MJ, Sun J et al. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl EnvironMicrobiol 2012; 78: 126-33.
16. Katiyar SK, Alastruey-Izquierdo A, Healey KR et al. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother 2012; 56: 6304-9.
17. Lackner M, Tscherner M, Schaller M et al. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother 2014; 58: 3626-35.
18. Caramalho R, Maurer E, Binder U et al. Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother 2015; 59: 3663-5.
19. Monk BC, Tomasiak TM, Keniya MV et al. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci USA 2014; 111: 3865-70.
20. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 2011; 27: 343-50.
21. Pfaller MA, Messer SA, Woosley LN et al. Echinocandin and trazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J ClinMicrobiol 2013; 51: 2571-81.
22. Pfaller MA, Rhomberg PR, Messer SA et al. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis 2015; 82: 303-13.
23. Jensen RH, Johansen HK, Arendrup MC. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57: 614-7.
24. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009).J ClinMicrobiol 2011; 49: 325-34.
25. Chong Y, Shimoda S, Yakushiji H et al. Fatal candidemia caused by azoleresistant Candida tropicalis in patients with hematological malignancies. J Infect Chemother 2012; 18: 741-6.
26. PfallerMA, Moet GJ, Messer SA et al. Candida bloodstreaminfections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY antimicrobial surveillance program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-6.
27. Shields RK, Nguyen MH, Press EG et al. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013; 57: 3528-35.
28. Cantón E, Pemán J, Quindós G et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, andCandida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011; 55: 5590-6.
29. Xiang M-J, Liu J-Y, Ni P-H et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 2013; 13: 386-93.
30. ArendrupMC, Garcia-Effron G, Lass-Flörl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob Agents Chemother 2010; 54: 426-39.
31. Chau AS, Mendrick CA, Sabatelli FJ et al. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48: 2124-31.
32. Goldman GH, da Silva Ferreira ME, dos Reis Marques E et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004; 50: 25-32.
33. Lee M-K, Williams LE, Warnock DWet al. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-24.
34. Flowers SA, Colon B, Whaley SG et al. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 2015; 59: 450-60.
35. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediatedantifungal drug resistance. ClinMicrobiol Rev 2009; 22: 291-321.